Arcus Biosciences, Inc.

Samuel Lawrie Drew

Manmohan Reddy Leleti

Kenneth Victor Lawson

Joel Worley Beatty

Jay Patrick Powers

Guillaume Mata

Artur Karenovich Mailyan

Xuelei Yan

Brandon Reid Rosen

Jenna Leigh Jeffrey

Balint Gal

Matthew Epplin

Kai Yu

Clayton Hardman

Jaroslaw Kalisiak

Debashis Mandal

Erick Allen Lindsey

Anh Thu Tran

Steven Donald Jacob

Zhang Wang

Karl T Haelsig

Jeremy Thomas Andre Fournier

Yongli Su

Tezcan Guney

Hyunyoung Moon

Jeremy Fournier

Rhiannon Thomas-Tran

Dillon Harding Miles

Laurent Pierre Paul Debien

Rebecca Louise Grange

Ehesan Ui Sharif

Masa Podunavac

Dongdong Liu

Compounds that inhibit PI3Kγ, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by PI3Kγ.

2,3,5-trisubstituted pyrazolo[1,5-A]pyrimidine compounds

The present disclosure describes processes and intermediates useful for preparing a compound of Formula (Xa) or Formula (Xb). The processes and intermediates can be used to prepare the compounds of the disclosure at multigram or kilogram scale.

Process for preparing tetralin compounds

Compounds that inhibit HIF-2α, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2α.

Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha

The present disclosure is directed to compounds that are inhibitors of HIF-2α having a structure according to Formula I, and compositions containing those compounds. Methods of using the compounds for the treatment of diseases, disorders, or conditions are also described.

Inhibitors of HIF-2α and methods of use thereof

Compounds, such as compounds having Formula (I): wherein each variable is as described herein, that modulate the conversion of AMP to adenosine by 5′-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5′-nucleotidase, ecto is also provided.

CD73 inhibitors

Compounds that inhibit HIF-2&#x3b1;, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2&#x3b1;.

Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2&#x3b1;

Growing community of inventors

Millbrae, CA, United States of America

Samuel Lawrie Drew